Enliven Therapeutics (ELVN) Profit After Tax Growth (1y) (2020 - 2026)
Enliven Therapeutics (ELVN) Profit After Tax Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 0.26% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 17,802.13% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 59.59% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -107.76% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 101.22% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Enliven Therapeutics | 3.33 Bn | 2.88 Bn | - | 14.72% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 14.72% |
| Dec 31, 2025 | -25.77% |
| Sep 30, 2025 | 12.99% |
| Jun 30, 2025 | -26.99% |
| Mar 31, 2025 | -25.53% |
| Dec 31, 2024 | -21.56% |
| Sep 30, 2024 | -11.30% |
| Jun 30, 2024 | -19.31% |
| Mar 31, 2024 | -54.43% |
| Dec 31, 2023 | -101.29% |
| Sep 30, 2023 | -97.13% |
| Jun 30, 2023 | -88.11% |
| Mar 31, 2023 | -69.85% |
| Dec 31, 2022 | 33.40% |
| Sep 30, 2022 | 22.66% |
| Jun 30, 2022 | 32.46% |
| Mar 31, 2022 | 15.48% |
| Dec 31, 2021 | -24.49% |
| Sep 30, 2021 | -9.64% |
| Jun 30, 2021 | -28.98% |